A Phase 1/2 Study of Replicating Arenavirus-based Vector(s) Encoding Prostate Cancer-Associated Antigens in Participants with Metastatic Castration-Resistant Prostate Cancer
Study of HB-302/HB-301 in Patients with Prostate Cancer
Sponsor: Hookipa
Enrolling: Male Patients Only
IRB Number: AAAU7983
U.S. Govt. ID: NCT05553639
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine whether HB-302/HB-301 therapy is safe and well tolerated. This will be the first time HB-302/HB-301 will be tested in humans. HB-302/HB-301 has not yet been approved by the Food and Drug Administration (FDA).
Investigator
Mark Stein, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with prostate cancer? Yes No
Do you agree to use contraception during the study and 5 months after the last dose of study drug? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162